Trial record 5 of 32 for:
" September 26, 2012":" October 26, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
Verified March 2014 by University of North Carolina, Chapel Hill
Information provided by (Responsible Party):
Prema Menezes, PhD, PA-C, University of North Carolina, Chapel Hill
First received: October 2, 2012
Last updated: March 4, 2014
Last verified: March 2014
The purpose of this research study is to evaluate how easy it is for female HIV- positive subjects taking Complera to comply with the dietary requirement using a food diary in the short term (4 weeks) and long term (24 weeks and 48 weeks) and to determine association between calorie intake and virologic suppression. A secondary goal of the study is to evaluate subjects' attitudes towards contraception.
||Observational Model: Case-Only
Time Perspective: Prospective
||CID 1213 - Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women After Switching to Fixed Dose Combination of Rilpivirine, Emtricitabine and Tenofovir DF
Primary Outcome Measures:
Secondary Outcome Measures:
Other Outcome Measures:
- Measurement of change in fasting lipids [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
- Measurement of change in fasting lipids [ Time Frame: Baseline ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||November 2014 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
HIV positive females ≥ 18 years of age who are currently on Complera with suppressed viral load (VL) defined as having VL <50 copies/ml in the 6 months prior to study entry and no known resistance to FTC, TDF, or rilpivirine. Subjects may or may not be of child bearing potential.
- HIV-1 infection documented by HIV serology or detectable viral load at any point prior to study entry or other documentation confirming HIV infection. If no documentation is available to confirm HIV infection, a rapid test may be performed to document HIV infection.
- HIV+ female ≥18 years old and obtaining care at UNC Health Care Infectious Diseases Clinic, Wake County Human Services Clinic, or Durham County Early Intervention Clinic. Patients receiving care at other clinics may be entered with approval of the study team.
- HIV viral load (VL) < 50 copies/ml as measured by any FDA-approved test for quantifying HIV-1 RNA during the six months prior to study entry (PSE). The timing of the viral load may be longer than 6 months depending on the schedule of the last clinic visit attended by the subject. The intent of the protocol was to assess viral load status at the previous clinic visit which may occur at an interval longer than six months due to the scheduling constraints of the UNC Infectious Diseases clinic. Viral loads drawn > than 6 months (but not > 8 months) prior to the study entry visit are acceptable. A single "blip" of > 50 and < 200 copies/ml is permissible provided the most recent VL is <50 copies/ml.
- No documented resistance to FTC, TDF or rilpivirine. Note: genotyping will not be performed on study. Subjects with no historical genotype will be considered to have no documented resistance.
- Able and willing to provide informed consent.
- In the opinion of the investigator, able to comply with study medication and procedures, including ability to complete food diary.
- Willing to receive monthly phone calls.
- Agreement between ID clinic provider and study team that clinical monitoring and care of patient will reside with the ID clinic provider. The study responsibility is limited to providing 48 weeks of Complera.
- Any condition which, in the opinion of the investigator, would be likely to interfere with ability to take the study medications appropriately and comply with the study protocol.
- Current active illness requiring systemic treatment and/or hospitalization until the individual completes therapy or, in the opinion of the investigator, is clinically stable on therapy for at least 7 days prior to study entry.
- Acute viral hepatitis.
- Known allergy/hypersensitivity to components of the study drugs or their formulations.
- Current or expected use of medication on the prohibited medication list.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01701895
|University of North Carolina at Chapel Hill
|Chapel Hill, North Carolina, United States, 27599-7215 |
|Contact: Erin Hoffman 919-843-0720 email@example.com |
|Contact: David Ragan, RN 919-966-2623 firstname.lastname@example.org |
|Principal Investigator: Prema Menezes, PhD, PA-C |
|Sub-Investigator: Joseph J Eron, Jr., MD |
|Sub-Investigator: David A Wohl, MD |
|Sub-Investigator: Cheryl Marcus, RN, BSN |
Prema Menezes, PhD, PA-C
||Prema Menezes, PhD, PA-C
||University of North Carolina, Chapel Hill
Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, Weissman S, Neidig J, Marcus C, Chesney M, Cohn SE, Wu AW. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001 Dec;54 Suppl 1:S77-90.
||Prema Menezes, PhD, PA-C, Clinical Assistant Professor of Medicine, University of North Carolina, Chapel Hill
History of Changes
|Other Study ID Numbers:
||CID 1213 - IRB 12-1550
|Study First Received:
||October 2, 2012
||March 4, 2014
||United States: Institutional Review Board
Keywords provided by University of North Carolina, Chapel Hill:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 22, 2014
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases